0001104659-21-070662 | 10-K/A | XBRL Viewer | DFP Healthcare Acquisitions Corp

Accrued expenses - related parties

231,323,610

50,000

Current liabilities:

Accrued expenses

50,000

26,500

17,500

Franchise tax payable

200,050

800

267,550

27,300

6,300,000

18,791,170

Class A common stock, $0.0001 par value; 21,975,605 and -0- shares subject to possible redemption at $10.00 per share at December 31, 2020 and December 31, 2019, respectively

25,358,720

27,300

Commitments and Contingencies

200,964,880

Stockholders' Equity:

Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding

13,341,349

24,425

(8,342,204)

(2,300)

5,000,010

22,700

231,323,610

50,000

Class A common stock

Stockholders' Equity:

290

Stockholders' Equity:

Beginning balance at Oct. 31, 2019

^[1]

$ 575

[1]

As of December 31, 2019, this number includes up to 750,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On March 13, 2020, the underwriter exercised its over-allotment option in full; thus, the Founder Shares were no longer subject to forfeiture.

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Temporary equity, redemption price per share	$ 10.00	$ 10.00
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares outstanding	5,750,000	5,750,000
Class A common stock
Temporary equity, shares subject to possible redemption	$ 0.0001	$ 0.0001
Temporary equity, shares subject to possible redemption	20,096,488	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	2,903,512	0
Common stock, shares outstanding	1,024,395	0
Common stock, shares subject to possible redemption	20,096,488	0
Class B common stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,750,000	5,750,000
Common stock, shares outstanding	5,750,000	5,750,000
Maximum common stock shares subject to forfeiture		750,000

STATEMENTS OF OPERATIONS - USD ($)	2 Months Ended	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2019	Dec. 31, 2020
General and administrative expenses	$ 1,500	$ 309,169
General and administrative expenses - related party	0	175,000
Franchise tax expense	800	199,700
Loss from operations	(2,300)	(683,869)
Interest income from investments in Trust Account	0	254,149
Change in fair value of derivative warrant liabilities	0	(7,583,670)
Offering costs associated with derivative warrant liabilities	0	(315,080)
Income/(loss) before income tax expense	(2,300)	(8,328,470)
Income tax expense	0	11,434
Net loss	$ (2,300)	(8,339,904)
Class A common stock
Interest income from investments in Trust Account		$ 254,000
Weighted average shares outstanding	0	23,000,000
Basic and diluted net loss per share	$ 0.00	$ 0.00
Class B common stock
Net loss	$ (2,300)	$ (8,300,000)
Weighted average shares outstanding	5,000,000	5,602,459
Basic and diluted net loss per share	$ 0.00	$ (1.49)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)

Common Stock

Class A common stock

Common Stock

Class B common stock

Additional Paid-In Capital

Class B common stock

Additional Paid-In Capital

Accumulated Deficit

Class B common stock

Total

$ 0

Sale of units in initial public offering

^[1],[2]

$ 575

$ 24,425

$ 25,000

Sale of units in initial public offering (in shares)

^[1],[2]

5,750,000

Ending balance at Dec. 31, 2019

(2,300)

$ (2,300)

(2,300)

$ 575

24,425

(2,300)

22,700

Ending balance (in shares) at Dec. 31, 2019

5,750,000

Maximum common stock shares subject to forfeiture

750,000

Ending balance at Mar. 31, 2020

(776,839)

5,000,005

Beginning balance at Dec. 31, 2019

$ 575

24,425

(2,300)

22,700

Beginning balance (in shares) at Dec. 31, 2019

5,750,000

Ending balance at Jun. 30, 2020

(3,395,574)

5,000,010

Beginning balance at Dec. 31, 2019

$ 575

24,425

(2,300)

22,700

Beginning balance (in shares) at Dec. 31, 2019

5,750,000

Ending balance at Sep. 30, 2020

(5,812,234)

5,000,010

Beginning balance at Dec. 31, 2019

$ 575

24,425

(2,300)

22,700

Beginning balance (in shares) at Dec. 31, 2019

5,750,000

Sale of units in initial public offering

$ 2,300

223,270,200

223,272,500

Sale of units in initial public offering (in shares)

23,000,000

Offering costs

(10,110,406)

Sale of private placement warrants to Sponsor in private placement

1,120,000

Common stock subject to possible redemption

$ (2,010)

(200,962,870)

(200,964,880)

Common stock subject to possible redemption (in shares)

(20,096,488)

Ending balance at Dec. 31, 2020

(8,339,904)

$ (8,300,000)

(8,339,904)

$ 290

$ 575

$ 13,341,349

$ (8,342,204)

5,000,010

Ending balance (in shares) at Dec. 31, 2020

2,903,512

5,750,000

Beginning balance at Mar. 31, 2020

5,000,005

Ending balance at Jun. 30, 2020

(2,618,735)

5,000,010

Ending balance at Sep. 30, 2020

(2,416,660)

$ 5,000,010

[1]	The share amounts have been retroactively restated to reflect the split of Class B common stock on February 19, 2020 resulting in 5,750,000 shares outstanding (see Note 4).
[2]	This number excludes an aggregate of up to 750,000 Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

STATEMENTS OF CASH FLOWS - USD ($)	2 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2019	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Cash Flows from Operating Activities:
Net loss	$ (2,300)	$ (776,839)	$ (3,395,574)	$ (5,812,234)	$ (8,339,904)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on investments held in Trust Account	0	(42,685)	(121,508)	(194,901)	(254,149)
Offering costs associated with derivative warrant liabilities	0	315,080	315,080	315,080	315,080
Change in fair value of derivative warrant liabilities	0	416,670	2,919,670	5,198,670	7,583,670
Changes in operating assets and liabilities:
Prepaid expenses	0				(152,474)
Accrued expenses	1,500				48,500
Accrued expenses - related parties	0				17,500
Franchise tax payable	800				199,250
Net cash used in operating activities	0				(582,527)
Cash Flows from Investing Activities
Cash deposited in Trust Account	0				(230,000,000)
Net cash used in investing activities	0				(230,000,000)
Cash Flows from Financing Activities:
Proceeds received from note payable to related party	0				200,000
Repayment of note payable to related party	0				(200,000)
Proceeds received from initial public offering, gross	0				230,000,000
Proceeds received from private placement	0				5,600,000
Offering costs paid	0				(4,125,486)
Net cash provided by financing activities	25,000				231,474,514
Net increase in cash	25,000				891,987
Cash - beginning of the period	0	25,000	25,000	25,000	25,000
Cash - end of the period	25,000				916,987
Supplemental disclosure of noncash activities:
Offering costs included in accrued expenses	25,000
Deferred underwriting commissions in connection with the initial public offering	0				6,300,000
Initial value of Class A common stock subject to possible redemption	0	208,956,930	208,956,930	208,956,930	208,956,930
Change in value of Class A common stock subject to possible redemption	0	$ (428,980)	$ (3,047,720)	$ (5,464,380)	$ (7,992,050)
Class B common stock
Cash Flows from Financing Activities:
Proceeds from issuance of Class B common stock to Sponsor	$ 25,000

Organization, Business Operations and Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Organization, Business Operations and Basis of Presentation
Organization, Business Operations and Basis of Presentation	Note 1 — Organization, Business Operations and Basis of Presentation Incorporation DFP Healthcare Acquisitions Corp. (the “Company”) was incorporated as a Delaware corporation on November 1, 2019. Sponsor The Company’s sponsor is DFP Sponsor LLC, a Delaware limited liability company (the “Sponsor”). Business Purpose The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more operating businesses that it has not yet selected (“Business Combination”). The Company has neither engaged in any operations nor generated revenue to date. As of December 31, 2020, the Company had not commenced any operations. All activity for the period from November 1, 2019 (inception) through December 31, 2020 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”) described below, and since the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering, although substantially all of the net proceeds of the Initial Public Offering are intended to be generally applied toward completing a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully complete a Business Combination. Financing The registration statement for the Company’s Initial Public Offering was declared effective by the Securities and Exchange Commission (the “SEC”) on March 10, 2020. On March 13, 2020, the Company consummated its Initial Public Offering of 23,000,000 units (the “Units” and, with respect to the Class A common stock included in the Units being offered, the “Public Shares”), including 3,000,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $230.0 million, and incurring offering costs of approximately $10.4 million, inclusive of approximately $6.3 million in deferred underwriting commissions (Note 3). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 3,733,334 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to the Sponsor, generating proceeds of $5.6 million (Note 4). Trust Account Upon the closing of the Initial Public Offering and the Private Placement, $230.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (the “Trust Account”) and invested in permitted United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, which the Company refers to as the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act that invest only in direct U.S. government treasury obligations. The Company’s second amended and restated certificate of incorporation provides that, other than the withdrawal of interest earned on the funds that may be released to the Company to pay taxes, none of the funds held in Trust Account will be released until the earlier of: (i) the completion of the Business Combination; (ii) the redemption of the Public Shares to its holders (the “Public Stockholders”) properly tendered in connection with a stockholder vote to amend the Company’s second amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares or with respect to any other material provision relating to stockholders’ rights or pre-initial Business Combination activity, or (iii) the redemption of 100% of the Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering. The Company, after signing a definitive agreement for a Business Combination, will either (i) seek stockholder approval of the Business Combination at a meeting called for such purpose in connection with which stockholders may seek to redeem their shares, regardless of whether they vote for or against the Business Combination, for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) and/or to pay its taxes, or (ii) provide the Public Stockholders with the opportunity to sell their shares to the Company by means of a tender offer for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to commencement of the tender offer, including interest earned on the funds held in the Trust Account and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) and/or to pay taxes. The decision as to whether the Company will seek stockholder approval of the Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the outstanding shares of common stock voted are voted in favor of the Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001. If the Company holds a stockholder vote in connection with a Business Combination, a Public Stockholder will have the right to redeem its shares for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) and/or to pay its taxes. As a result, such common stock is recorded at redemption amount and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with FASB, ASC 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account is initially anticipated to be $10.00 per public share ($230.0 million held in the Trust Account divided by 23,000,000 public shares). The Company will have 24 months from the closing of the Initial Public Offering, or until March 13, 2022, to complete its initial Business Combination (the “ Combination Period”). If the Company does not complete a Business Combination within this period of time, it will (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the Public Shares for a per share pro rata portion of the Trust Account, including interest and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) (less taxes payable and up to $100,000 of such net interest to pay dissolution expenses) and (iii) as promptly as possible following such redemption, liquidate and dissolve the balance of the Company’s net assets to its remaining stockholders, as part of its plan of dissolution and liquidation. The Sponsor and the Company’s officers and directors (the “initial stockholders”) have entered into a letter agreement with the Company, pursuant to which they have waived their rights to participate in any redemption with respect to their Founder Shares (as defined below); however, if the initial stockholders acquire shares of common stock in or after the Initial Public Offering, they will be entitled to a pro rata share of the Trust Account upon the Company’s redemption of common stock or liquidation in the event the Company does not complete a Business Combination within the required time period. In the event of such a liquidating distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the initial price per Unit in the Initial Public Offering. Basis of Presentation The accompanying financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used. Going Concern As of December 31, 2020, the Company had approximately $0.9 million in its operating bank account, working capital of approximately $0.8 million, and approximately $254,000 of interest income available in the Trust Account for working capital requirements (subject to an annual limit of $500,000) and/or to pay for the Company’s tax obligations, if any. The Company’s liquidity needs to date have been satisfied through a $25,000 contribution from the Sponsor in exchange for the issuance of the Founder Shares to the Sponsor, the Note (defined below) of $200,000 from the Sponsor, and the proceeds from the consummation of the Private Placement not held in the Trust Account. On March 13, 2020, the Company repaid the Note in full to the Sponsor. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company with Working Capital Loans (see Note 4). As of December 31, 2020, there were no Working Capital Loans outstanding. In connection with the Company's assessment of going concern considerations in accordance with FASB ASC Topic 205-40, " Presentation of Financial Statements - Going Concern," management has determined that the liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company's ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after March 13, 2022.

Restatement of previously issued financial statements

12 Months Ended

Dec. 31, 2020

Restatement of previously issued financial statements

Restatement of previously issued financial statements

Note 2 — Restatement of previously issued financial statements

In May 2021, the Audit Committee of the Company, in consultation with management, concluded that, because of a misapplication of the accounting guidance related to its public and private placement warrants to purchase Class A ordinary shares that the Company issued in March 2020 (the “Warrants”), the Company’s previously issued financial statements for the Affected Periods should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Periods included in this Annual Report.

On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance in March 2020, the Company’s warrants were accounted for as equity within the Company’s previously reported balance sheets. After discussion and evaluation, with the Company’s audit committee, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement.

Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on our application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40). The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for Warrants issued in March 2020, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company’s statement of operations each reporting period.

Impact of the Restatement

The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Periods is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities.


	As of December 31, 2020
			Restatement
	As Previously Reported		Adjustment		As Restated

Balance Sheet
Total assets	$	231,323,610	$	—	$	231,323,610
Liabilities and stockholders’ equity
Total current liabilities	$	267,550	$	—	$	267,550
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		18,791,170		18,791,170
Total liabilities		6,567,550		18,791,170		25,358,720
Class A common stock, $0.0001 par value; shares subject to possible redemption		219,756,050		(18,791,170)		200,964,880
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		102		188		290
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,442,787		7,898,562		13,341,349
Accumulated deficit		(443,454)		(7,898,750)		(8,342,204)
Total stockholders’ equity		5,000,010		—		5,000,010
Total liabilities and stockholders’ equity	$	231,323,610	$	—	$	231,323,610


	For the Year Ended December 31, 2020
			Restatement
	As Previously Reported		Adjustment		As Restated

Statement of Operations
Loss from operations	$	(683,869)	$	—	$	(683,869)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(7,583,670)		(7,583,670)
Financing costs - derivative warrant liabiltiies		—		(315,080)		(315,080)
Interest income from investments in Trust Account		254,149		—		254,149
Income tax expense		(11,434)		—		(11,434)
Total other (expense) income		242,715		(7,898,750)		(7,656,035)
Net loss	$	(441,154)	$	(7,898,750)	$	(8,339,904)

Basic and Diluted weighted-average Class A common stock outstanding		23,000,000				23,000,000
Basic and Diluted net loss per Class A common shares	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock outstanding		5,602,459		—		5,602,459
Basic and Diluted net loss per Class B common shares	$	(0.08)	$	(1.41)	$	(1.49)


	For the Year Ended December 31, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Statement of Cash Flows
Net loss	$	(441,154)	$	(7,898,750)	$	(8,339,904)
Change in fair value of derivative warrant liabilities		—		7,583,670		7,583,670
Financing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(408,380)		(7,583,670)		(7,992,050)

In addition, the impact to the balance sheet dated March 13, 2020, filed by the Company with the SEC on Form 8-K on March 19, 2020 related to the impact of accounting for the warrants as liabilities at fair value resulted in a $11.2 million increase to the derivative liabilities line item at March 13, 2020 and offsetting decrease to the Class A common stock subject to possible redemption mezzanine equity line item. In addition, the allocation of associated offering costs to the derivative warrant liabilities resulted in an increase to additional paid-in-capital of $0.3 million and an offsetting decrease to the accumulated deficit. There is no change to total stockholders’ equity at the reported balance sheet date.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 3 — Summary of Significant Accounting Policies

Basis of presentation

The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company has no subsidiaries.

As described in Note 2—Restatement of Previously Issued Financial Statements, the Company’s financial statements for the period as of December 31, 2020, and the year ended December 31, 2020, as of September 30, 2020 and for the three and nine months ended September 30, 2020, as of June 30, 2020 and for the three and six months ended June 30, 2020, and as of March 31, 2020 and for the three months ended March 31, 2020 (collectively, the “Affected Periods”), are restated in this Annual Report on Form 10-K/A (Amendment No. 1) (this “Annual Report”) to correct the misapplication of accounting guidance related to the Company’s warrants in the Company’s previously issued audited and unaudited condensed financial statements for such periods. The restated financial statements are indicated as “Restated” in the audited and unaudited condensed financial statements and accompanying notes, as applicable. See Note 2—Restatement of Previously Issued Financial Statements for further discussion.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events. Accordingly, the actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of December 31, 2020, and 2019.

Investments Held in the Trust Account

The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in net gain on investments, dividends and interest held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in the Trust Account were determined using available market information.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation limit of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received for sale of an asset, or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

As of December 31, 2020, and 2019, the carrying values of cash, prepaid expenses, accounts payable, accrued expenses, accrued expenses - related party, and tax obligations approximate their fair values due to the short-term nature of the instruments. The Company’s portfolio of marketable securities held in the Trust Account is comprised mainly of investments in U.S. Treasury securities with an original maturity of 185 days or less. The fair value for trading securities is determined using quoted market prices in active markets.

Offering Costs

The Company complies with the requirements of the ASC 340‑10‑S99‑1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering and were charged to stockholders’ equity upon the completion of the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering.

Derivative Warrant Liabilities

The Company does not use derivative instruments to hedge its exposures to cash flow, market or foreign currency risks. Management evaluates all of the Company’s financial instruments, including issued warrants to purchase its Class A common stock, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

The Company issued 5,750,000 warrants to purchase Class A common stock to investors in the Company’s Initial Public Offering, including the over-allotment, and simultaneously issued 3,733,334 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants have been estimated using a Monte Carlo simulation model each measurement date. The fair value of Public Warrants issued in connection with the Initial Public Offering have subsequently been measured based on the listed market price of such warrants.

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A common stock (including Class A common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A common stock is classified as stockholders’ equity. The Company’s Class A common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at December 31, 2020 , 20,096,488 shares of Class A common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheets.

Net Income (Loss) Per Share of Common Stock

Net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the Private Placement to purchase an aggregate of 9,483,334 of the Company’s Class A common stock in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method.

The Company’s statements of operations include a presentation of loss per share for common stock subject to redemption in a manner similar to the two-class method of income (loss) per share. Net income (loss) per common share, basic and diluted for Class A common stock is calculated by dividing the interest income earned on the investments held in the Trust Account of approximately $254,000, less approximately $211,000 of maximum allowance for tax obligations, minus approximately $43,000 for working capital allowance, resulting in no income for Class A common stock for the year ended December 31, 2020, by the weighted average number of Class A common stock outstanding for the period. Net loss per common stock, basic and diluted for Class B common stock is calculated by dividing the net loss of approximately $8.3 million, less income attributable to Class A common stock of $0, resulting in a net loss of approximately $8.3 million for the year ended December 31, 2020, by the weighted average number of Class B common stock outstanding for the period.

For the period from November 1, 2019 (inception) through December 31, 2019, net loss per common stock, basic and diluted for Class B common stock is calculated by dividing the net loss of approximately $2,300, by the weighted average number of Class B common stock outstanding for the period excluding 750,000 shares that were subject to forfeiture.

Income Taxes

The Company complies with the accounting and reporting requirements of Financial Accounting Standards Board Accounting Standard Codification, or FASB ASC, 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

There were no unrecognized tax benefits as of December 31, 2020 or 2019. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2020 or 2019. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Initial Public Offering	12 Months Ended
Initial Public Offering	Dec. 31, 2020
Initial Public Offering
Initial Public Offering	Note 4 —Initial Public Offering Public Units On March 13, 2020, the Company consummated its Initial Public Offering of 23,000,000 Units, including 3,000,000 Over-Allotment Units, at $10.00 per Unit, generating gross proceeds of $230.0 million, and incurring offering costs of approximately $10.4 million, inclusive of approximately $6.3 million in deferred underwriting commissions. Of the Units sold in the Initial Public Offering, 5,000,000 Units were purchased by certain domestic private pooled investment vehicles managed by Deerfield Management Company, L.P. and its affiliates (the “Deerfield Funds”). Each Unit consists of one of the Company’s shares of Class A common stock, $0.0001 par value, and one-fourth of one redeemable warrant (the “Warrants”). Each whole Warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share. The exercise price and number of shares of Class A common stock issuable upon exercise of the Warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2020
Related Party Transactions
Related Party Transactions	Note 5 — Related Party Transactions Founder Shares On December 30, 2019, the Sponsor received 4,312,500 shares of Class B common stock (the “Founder Shares”) in exchange for a capital contribution of $25,000, or approximately $0.004 per share. In January 2020, the Sponsor transferred 100,000 Founder Shares to each of Steven Hochberg, the Company’s President and Chief Executive Officer, Christopher Wolfe, the Company’s Chief Financial Officer and Secretary, and Richard Barasch, the Company’s Executive Chairman, and 30,000 Founder Shares to each of Dr. Jennifer Carter, Dr. Mohit Kaushal and Dr. Gregory Sorensen, the Company’s independent director nominees, for the same per-share price initially paid by the Sponsor, resulting in the Sponsor holding 3,922,500 Founder Shares. On February 19, 2020, the Company effected a split of its Class B common stock resulting in the Sponsor holding 5,360,000 Founder Shares, resulting in an increase in the total number of Founder Shares from 4,312,500 to 5,750,000. All shares and associated amounts have been retroactively restated. Of the 5,750,000 Founder Shares, up to 750,000 shares were subject to forfeiture by the initial stockholders depending on the exercise of the underwriters’ over-allotment option. The underwriters exercised their over-allotment option in full on March 13, 2020; thus, the Founder Shares are no longer subject to forfeiture. The Founder Shares are identical to the shares of Class A common stock included in the Units being sold in the Initial Public Offering except that the Founder Shares are subject to certain transfer restrictions. The initial stockholders have agreed not to transfer, assign or sell any of their Founder Shares until the earlier of (A) one year after the completion of the Company’s initial Business Combination, or earlier if, subsequent to the Company’s initial Business Combination, the closing price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30‑trading day period commencing at least 150 days after the Company’s initial Business Combination and (B) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction after the initial Business Combination that results in all of the Company’s stockholders having the right to exchange their common stock for cash, securities or other property. Private Placement Warrants Simultaneously with the closing of the Initial Public Offering, the Company sold 3,733,334 Private Placement Warrants to the Sponsor at a price of $1.50 per Private Placement Warrant in a Private Placement, generating proceeds of $5.6 million. Each Private Placement Warrant entitles the holder to purchase one share of Class A common stock at $11.50 per share. Certain proceeds of the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination, the proceeds of the Private Placement will be part of the liquidating distribution to the Public Stockholders and the Warrants issued to the Sponsor will expire worthless. Sponsor Loan The Sponsor agreed to loan the Company up to an aggregate of $200,000 by the issuance of an unsecured promissory note (the “Note”) to cover expenses related to this Initial Public Offering. The Note was payable, without interest, upon the completion of the Initial Public Offering. The Company received the $200,000 proceeds under the Note and repaid this Note in full on March 13, 2020. Administrative Services Agreement Commencing on the date that the Company’s securities were first listed on Nasdaq, the Company has paid and will pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to members of the Company’s management team. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying such monthly fees. The Company incurred $100,000 and $0, in expenses in connection with such services during the year ended December 31, 2020 and the period from November 1, 2019 (inception) through December 31, 2019, respectively, as included in general and administrative expenses - related party on the accompanying statements of operations. As of December 31, 2020, and 2019, the Company had $10,000 and $0 in connection with such services in accrued expenses to related parties, respectively, as included in the accompanying balance sheets. Wolfe Strategic Services Agreement Commencing on the date that the Company’s securities were first listed on Nasdaq, the Company will pay and has paid its Chief Financial Officer, Christopher Wolfe, $7,500 per month for his services prior to the initial Business Combination. The Company incurred $75,000 and $0 in expenses in connection with such services during the year ended December 31, 2020 and the period from November 1, 2019 (inception) through December 31, 2019, respectively, as included in general and administrative expenses - related party on the accompanying statement of operations. As of December 31, 2020, and 2019, the Company had $7,500 and $0 in connection with such services in accrued expenses to related parties, respectively, as included in the accompanying balance sheets. Working Capital Loans In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required for working capital (the “Working Capital Loans”). Up to $1.1 million of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant at the option of the lender. Such warrants would be identical to the Private Placement Warrants. As of December 31, 2020, except for the foregoing, the terms of such loans, if any, have not been determined, no written agreements exist with respect to such loans and no amounts have been borrowed under such loans to date.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2020
Commitments and Contingencies
Commitments and Contingencies	Note 6 — Commitments and Contingencies Registration Rights The initial stockholders and holders of the Private Placement Warrants are entitled to registration rights pursuant to a registration rights agreement. The initial stockholders and holders of the Private Placement Warrants will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option to purchase up to 3,000,000 additional Units to cover any over-allotments, at the initial public offering price less the underwriting discounts and commissions. The warrants that were issued in connection with the 3,000,000 over-allotment Units are identical to the public warrants and have no net cash settlement provisions. The underwriters exercised the over-allotment option in full on March 13, 2020. The underwriters did not receive any underwriting discounts or commission on the Units purchased by the Deerfield Funds. The Company paid an underwriting discount of 2.0% of the per Unit offering price, or $3.6 million, at the closing of the Initial Public Offering, with an additional fee (the “Deferred Underwriting Fees”) of 3.5% of the gross offering proceeds, or $6.3 million, payable upon the Company's completion of an Initial Business Combination. The Deferred Underwriting Fees will become payable to the underwriters from the amounts held in the Trust Account solely in the event the Company completes its initial Business Combination. Risks and uncertainties Management continues to evaluate the impact of the COVID-19 pandemic on its industry and has concluded that, while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Derivative Warrant Liabilities

12 Months Ended

Dec. 31, 2020

Derivative Warrant Liabilities

Derivative Warrant Liabilities

Note 7 — Derivative Warrant Liabilities

As of December 31, 2020, the Company had 5,750,000 Public Warrants and 3,733,334 Private Warrants outstanding.

Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their Public Warrants on a cashless basis under certain circumstances). The Company has agreed that, as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its best efforts to file with the SEC and have declared effective a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Company’s shares of Class A common stock are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination and they will be non-redeemable for cash so long as they are held by the initial purchasers of the Private Placement Warrants or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers of the Private Placement Warrants or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the warrants included in the Units being sold in the Initial Public Offering.

The Company may call the Public Warrants for redemption:

in whole and not in part;

at a price of $0.01 per warrant;

upon a minimum of 30 days’ prior written notice of redemption; and

if, and only if, the last reported sales price of the Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within the 30‑trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.

In addition, commencing ninety days after the warrants become exercisable, the Company may redeem the outstanding warrants for shares of Class A common stock:

in whole and not in part;

at a price of $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table set forth under “Description of Securities—Warrants—Public Stockholders’ Warrants” based on the redemption date and the “fair market value” of our Class A common stock (as defined below) except as otherwise described in “Description of Securities—Warrants—Public Stockholders’ Warrants”;

if, and only if, the last reported sale price of its Class A common stock equals or exceeds $10.00 per share (as adjusted per stock splits, stock dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which it sends the notice of redemption to the warrant holders;

if, and only if, the Private Placement Warrants are also concurrently exchanged at the same price (equal to a number of shares of Class A common stock) as the outstanding Public Warrants, as described above; and

if, and only if, there is an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30‑day period after written notice of redemption is given.

The “fair market value” of the Company’s Class A common stock shall mean the average last reported sale price of its Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. This redemption feature differs from the typical warrant redemption features used in other blank check offerings.

No fractional shares of Class A common stock will be issued upon redemption. If, upon redemption, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of shares of Class A common stock to be issued to the holder.

Pursuant to the warrant agreement, references above to Class A common stock shall include a security other than Class A common stock into which the Class A common stock has been converted or exchanged for in the event the Company is not the surviving company in its initial Business Combination.

In no event will the Company be required to net cash settle any warrant. If the Company does not complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2020
Stockholders' Equity
Stockholders' Equity	Note 8 — Stockholders’ Equity Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. At December 31, 2020, and 2019, there are no shares of preferred stock issued or outstanding. Class A Common Stock — The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. As of December 31, 2020, there were 23,000,000 shares of Class A common stock issued or outstanding, including 21,975,605 shares of Class A common stock subject to possible redemption. As of December 31, 2019, there were no shares of Class A common stock issued or outstanding. Class B Common Stock — The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of the Company’s Class B common stock are entitled to one vote for each share. On December 30, 2019, the Company initially issued 4,312,500 shares of Class B common stock. On February 19, 2020, in connection with the proposed increase of the size of the Initial Public Offering, the Company effected a split of its Class B common stock resulting in the Sponsor holding 5,360,000 Founder Shares and an increase in the total number of Class B common stock outstanding from 4,312,500 to 5,750,000. Of the 5,750,000 shares of Class B common stock outstanding, up to 750,000 shares were subject to forfeiture to the Company to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial stockholders would collectively own 20% of the Company’s issued and outstanding common stock after the Initial Public Offering. All shares and associated amounts have been retroactively restated. The underwriters exercised their over-allotment option in full on March 13, 2020; thus, the 750,000 shares of Class B common stock were no longer subject to forfeiture. As of December 31, 2020, and 2019, there were 5,750,000 shares of Class B common stock issued outstanding. The Class B common stock will automatically convert into Class A common stock at the time of the Initial Business Combination on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed issued in connection with the initial Business Combination, the number of shares of Class A common stock issuable upon conversion of all Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the total number of shares of Class A common stock outstanding after such conversion (after giving effect to any redemptions of shares of Class A common stock by Public Stockholders), including the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any shares of Class A common stock or equity-linked securities or rights exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, officers or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than one-for-one basis.

Fair Value Measurements

12 Months Ended

Dec. 31, 2020

Fair Value Measurements

Fair Value Measurements

Note 9 — Fair Value Measurements

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2020 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.


	Quoted Prices in		Significant Other		Significant Other
	Active Markets		Observable Inputs		Unobservable Inputs
Description	(Level 1)		(Level 2)		(Level 3)
Assets
Assets held in Trust Account:
U.S. Treasury securities	$	230,253,395	$	—	$	—
Cash equivalents - money market funds		754		—		—
	$	230,254,149	$	—	$	—

Liabilities
Derivative warrant liabilities -Public Warrants	$	11,212,500	$	—	$	—
Derivative warrant liabilities -Private Warrants	$	—	$	—	$	7,578,670

Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. There were no transfers between levels for the year ended December 31, 2020. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in June 2020, upon trading of the Public Warrants in an active market.

Level 1 instruments include investments in money market funds and U.S. Treasury securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.

The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants have been estimated using a Monte Carlo simulation model each measurement date. The fair value of Public Warrants issued in connection with the Initial Public Offering have been measured based on the listed market price of such warrants, a Level 1 measurement, beginning in June 2020.

The estimated fair value of the Private Placement Warrants, and the Public Warrants prior to being separately listed and traded, is determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its Class A common stock warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s Class A common stock that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2019.

The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement:


	As of March 13, 2020			As of December 31, 2020
Stock Price	$	9.71		$	10.80
Volatility		18.2	%		24.0	%
Expected life of the options to convert		6.55			5.75
Risk-free rate		0.85	%		0.47	%
Dividend yield		0.0	%		0.0	%

The change in the fair value of the derivative warrant liabilities measured with Level 3 inputs for the year ended December 31, 2020 is summarized as follows:


Level 3 derivative warrant liabilities at January 1, 2020	$	—
Issuance of Public and Private Warrants		11,207,500
Transfer of Public Warrants to Level 1		(6,957,500)
Change in fair value of derivative warrant liabilities		3,328,670
Level 3 derivative warrant liabilities at December 31, 2020	$	7,578,670

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Quarterly financial information (unaudited)

12 Months Ended

Dec. 31, 2020

Quarterly financial information (unaudited)

Quarterly financial information (unaudited)

Note 10. Quarterly financial information (unaudited)

The following tables contain unaudited quarterly financial information for the three months ended March 31, 2020, for the three and six months ended June 30, 2020, and for the three and nine months ended September 30, 2020 that has been updated to reflect the restatement and revision of the Company’s financial statements as described in Note 2—Restatement of Previously Issued Financial Statements. The restatement and revision had no impact on net cash flows from operating, investing or financing activities. The Company has not amended its previously filed Quarterly Report on Form 10-Q for the Affected Period. The financial information that has been previously filed or otherwise reported for the Affected Period is superseded by the information in this Annual Report, and the financial statements and related financial information for the Affected Period contained in such previously filed report should no longer be relied upon.


	As of March 31, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Balance Sheet
Total assets	$	231,843,054	$	—	$	231,843,054
Liabilities and stockholders’ equity
Total current liabilities	$	390,929	$	—	$	390,929
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		11,624,170		11,624,170
Total liabilities		6,690,929		11,624,170		18,315,099
Class A common stock, $0.0001 par value; shares subject to possible redemption		220,152,120		(11,624,170)		208,527,950
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		98		117		215
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,046,721		731,633		5,778,354
Accumulated deficit		(47,389)		(731,750)		(779,139)
Total stockholders’ equity		5,000,005		—		5,000,005
Total liabilities and stockholders’ equity	$	231,843,054	$	—	$	231,843,054


	For the Three Months Ended March 31, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(87,774)	$	—	$	(87,774)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(416,670)		(416,670)
Financing cost - derivative warrant liabilities		—		(315,080)		(315,080)
Interest earned on marketable securities held in Trust Account		42,685		—		42,685
Total other (expense) income		42,685		(731,750)		(689,065)
Net loss	$	(45,089)	$	(731,750)	$	(776,839)

Basic and Diluted weighted-average Class A common stock		23,000,000				23,000,000
Basic and Diluted net loss per Class A common stock	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock		5,750,000		(593,407)		5,156,593
Basic and Diluted net loss per Class B common stock	$	(0.01)	$	(0.14)	$	(0.15)


	For the Three Months Ended March 31, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Unaudited Condensed Statement of Cash Flows
Net loss	$	(45,089)	$	(731,750)	$	(776,839)
Change in fair value of derivative warrant liabilities		—		416,670		416,670
Fiancing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(12,310)		(416,670)		(428,980)


	As of June 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Balance Sheet
Total assets	$	231,466,990	$	—	$	231,466,990
Liabilities and stockholders’ equity
Total current liabilities	$	130,600	$	—	$	130,600
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		14,127,170		14,127,170
Total liabilities		6,430,600		14,127,170		20,557,770
Class A common stock, $0.0001 par value; shares subject to possible redemption		220,036,380		(14,127,170)		205,909,210
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		100		141		241
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,162,459		3,234,609		8,397,068
Accumulated deficit		(163,124)		(3,234,750)		(3,397,874)
Total stockholders’ equity		5,000,010		—		5,000,010
Total liabilities and stockholders’ equity	$	231,466,990	$	—	$	231,466,990


	For the Three Months Ended June 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(194,558)	$	—	$	(194,558)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(2,503,000)		(2,503,000)
Interest earned on marketable securities held in Trust Account		78,823		—		78,823
Total other (expense) income		78,823		(2,503,000)		(2,424,177)
Net loss	$	(115,735)	$	(2,503,000)	$	(2,618,735)

Basic and Diluted weighted-average Class A common stock		23,000,000				23,000,000
Basic and Diluted net loss per Class A common stock	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock		5,750,000				5,750,000
Basic and Diluted net loss per Class B common stock	$	(0.03)	$	(0.43)	$	(0.46)


	For the Six Months Ended June 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(282,332)	$	—	$	(282,332)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(2,919,670)		(2,919,670)
Financing cost - derivative warrant liabilities		—		(315,080)		(315,080)
Interest earned on marketable securities held in Trust Account		121,508		—		121,508
Total other (expense) income		121,508		(3,234,750)		(3,113,242)
Net loss	$	(160,824)	$	(3,234,750)	$	(3,395,574)

Basic and Diluted weighted-average Class A common shares outstanding		23,000,000		—		23,000,000
Basic and Diluted net loss per Class A share	$	0.00		—	$	0.00
Basic and Diluted weighted-average Class B common shares outstanding		5,750,000		(296,703)		5,453,297
Basic and Diluted net loss per Class B share	$	(0.04)	$	(0.58)	$	(0.62)


	For the Six Months Ended June 30, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Unaudited Condensed Statement of Cash Flows
Net loss	$	(160,824)	$	(3,234,750)	$	(3,395,574)
Change in fair value of derivative warrant liabilities		—		2,919,670		2,919,670
Fiancing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(128,050)		(2,919,670)		(3,047,720)


	As of September 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Balance Sheet
Total assets	$	231,395,659	$	—	$	231,395,659
Liabilities and stockholders’ equity
Total current liabilities	$	196,929	$	—	$	196,929
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		16,406,170		16,406,170
Total liabilities		6,496,929		16,406,170		22,903,099
Class A common stock, $0.0001 par value; shares subject to possible redemption		219,898,720		(16,406,170)		203,492,550
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		101		164		265
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,300,118		5,513,586		10,813,704
Accumulated deficit		(300,784)		(5,513,750)		(5,814,534)
Total stockholders’ equity		5,000,010		—		5,000,010
Total liabilities and stockholders’ equity	$	231,395,659	$	—	$	231,395,659


	Three Months Ended September 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(198,480)	$	—	$	(198,480)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(2,279,000)		(2,279,000)
Interest income from investments in Trust Account		73,393		—		73,393
Income tax expense		(12,573)		—		(12,573)
Total other (expense) income		60,820		(2,279,000)		(2,218,180)
Net loss	$	(137,660)	$	(2,279,000)	$	(2,416,660)

Basic and Diluted weighted-average Class A common stock		23,000,000				23,000,000
Basic and Diluted net loss per Class A common stock	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock		5,750,000				5,750,000
Basic and Diluted net loss per Class B common stock	$	(0.02)	$	(0.40)	$	(0.42)


	For the Nine Months Ended September 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(480,812)	$	—	$	(480,812)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(5,198,670)		(5,198,670)
Financing cost - derivative warrant liabilities		—		(315,080)		(315,080)
Interest income from investments in Trust Account		194,901		—		194,901
Income tax expense		(12,573)		—		(12,573)
Total other (expense) income		182,328		(5,513,750)		(5,331,422)
Net loss	$	(298,484)	$	(5,513,750)	$	(5,812,234)

Basic and Diluted weighted-average Class A common shares outstanding		23,000,000		—		23,000,000
Basic and Diluted net loss per Class A share	$	0.00		—	$	0.00
Basic and Diluted weighted-average Class B common shares outstanding		5,750,000		(197,080)		5,552,920
Basic and Diluted net loss per Class B share	$	(0.05)	$	(1.00)	$	(1.05)


	For the Nine Months Ended September 30, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Unaudited Condensed Statement of Cash Flows
Net loss	$	(298,484)	$	(5,513,750)	$	(5,812,234)
Change in fair value of derivative warrant liabilities		—		5,198,670		5,198,670
Fiancing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(265,710)		(5,198,670)		(5,464,380)

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Taxes

Income Taxes

Note 11 — Income Taxes

The Company’s taxable income primarily consists of interest income on the Trust Account, less any franchise taxes. The Company’s formation and operating costs are generally considered start-up costs and are not currently deductible.

The income tax provision (benefit) for the year ended December 31, 2020 consists of the following:


	December 31, 2020		December 31, 2019
Current
Federal	$	11,434	$	—
State		—		—
Deferred
Federal		(101,676)		(483)
State		—		—
Valuation allowance		101,676		483
Income tax provision		11,434		—

The provision for income taxes was deemed to be de minimis for the period from November 1, 2019 (inception) through December 31, 2019.

The Company’s net deferred tax assets are as follows:


	December 31, 2020		December 31, 2019
Deferred tax assets:
Start-up/Organization costs	$	101,676	$	315
Net operating loss carryforwards		—		168
Total deferred tax assets		101,676		483
Valuation allowance		(101,676)		(483)
Deferred tax asset, net of allowance	$	—	$	—

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December 31, 2020 and for the period from November 1, 2019 (inception) to December 31, 2019, the valuation allowance was $101,676 and $483, respectively.

A reconciliation of the statutory federal income tax rate (benefit) to the Company’s effective tax rate is as follows:


	December 31, 2020		December 31, 2019
Statutory federal income tax	$	(1,748,979)	$	(483)
Change in fair value of derivative warrant liabilities		(1,450,150)		—
Financing costs - derivative warrant liabilities		(2,503.20)		—
Change in valuation allowance		3,213,065		483
Income tax expense	$	11,434	$	—

There were no unrecognized tax benefits as of December 31, 2020, and 2019. No amounts were accrued for the payment of interest and penalties as of December 31, 2020, and 2019. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events
Subsequent Events	Note 12 — Subsequent Events Management has evaluated subsequent events and transactions that occurred after the balance sheet date up through May xx, 2021, the date the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Summary of Significant Accounting Policies

Basis of presentation

Use of Estimates

Cash and Cash Equivalents

Investments Held in the Trust Account

Concentration of Credit Risk

Fair Value of Financial Instruments

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

Offering Costs

Derivative Warrant Liabilities

Class A Common Stock Subject to Possible Redemption

Net Income (Loss) Per Share of Common Stock

Income Taxes

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Restatement of previously issued financial statements (Tables)

12 Months Ended

Dec. 31, 2020

Restatement of previously issued financial statements

Schedule of impact of the restatement on the balance sheets, statements of operations and statements of cash flows


	As of December 31, 2020
			Restatement
	As Previously Reported		Adjustment		As Restated

Balance Sheet
Total assets	$	231,323,610	$	—	$	231,323,610
Liabilities and stockholders’ equity
Total current liabilities	$	267,550	$	—	$	267,550
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		18,791,170		18,791,170
Total liabilities		6,567,550		18,791,170		25,358,720
Class A common stock, $0.0001 par value; shares subject to possible redemption		219,756,050		(18,791,170)		200,964,880
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		102		188		290
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,442,787		7,898,562		13,341,349
Accumulated deficit		(443,454)		(7,898,750)		(8,342,204)
Total stockholders’ equity		5,000,010		—		5,000,010
Total liabilities and stockholders’ equity	$	231,323,610	$	—	$	231,323,610


	For the Year Ended December 31, 2020
			Restatement
	As Previously Reported		Adjustment		As Restated

Statement of Operations
Loss from operations	$	(683,869)	$	—	$	(683,869)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(7,583,670)		(7,583,670)
Financing costs - derivative warrant liabiltiies		—		(315,080)		(315,080)
Interest income from investments in Trust Account		254,149		—		254,149
Income tax expense		(11,434)		—		(11,434)
Total other (expense) income		242,715		(7,898,750)		(7,656,035)
Net loss	$	(441,154)	$	(7,898,750)	$	(8,339,904)

Basic and Diluted weighted-average Class A common stock outstanding		23,000,000				23,000,000
Basic and Diluted net loss per Class A common shares	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock outstanding		5,602,459		—		5,602,459
Basic and Diluted net loss per Class B common shares	$	(0.08)	$	(1.41)	$	(1.49)


	For the Year Ended December 31, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Statement of Cash Flows
Net loss	$	(441,154)	$	(7,898,750)	$	(8,339,904)
Change in fair value of derivative warrant liabilities		—		7,583,670		7,583,670
Financing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(408,380)		(7,583,670)		(7,992,050)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value Measurements

Schedule of Company's assets that are measured at fair value on a recurring basis


	Quoted Prices in		Significant Other		Significant Other
	Active Markets		Observable Inputs		Unobservable Inputs
Description	(Level 1)		(Level 2)		(Level 3)
Assets
Assets held in Trust Account:
U.S. Treasury securities	$	230,253,395	$	—	$	—
Cash equivalents - money market funds		754		—		—
	$	230,254,149	$	—	$	—

Liabilities
Derivative warrant liabilities -Public Warrants	$	11,212,500	$	—	$	—
Derivative warrant liabilities -Private Warrants	$	—	$	—	$	7,578,670

Schedule of provides quantitative information regarding Level 3 fair value measurements inputs


	As of March 13, 2020			As of December 31, 2020
Stock Price	$	9.71		$	10.80
Volatility		18.2	%		24.0	%
Expected life of the options to convert		6.55			5.75
Risk-free rate		0.85	%		0.47	%
Dividend yield		0.0	%		0.0	%

Summary of change in the fair value of the derivative warrant liabilities measured with Level 3 inputs


Level 3 derivative warrant liabilities at January 1, 2020	$	—
Issuance of Public and Private Warrants		11,207,500
Transfer of Public Warrants to Level 1		(6,957,500)
Change in fair value of derivative warrant liabilities		3,328,670
Level 3 derivative warrant liabilities at December 31, 2020	$	7,578,670

Quarterly financial information (unaudited) (Tables)

12 Months Ended

Dec. 31, 2020

Quarterly financial information (unaudited)

Schedule of Unaudited Condensed Balance Sheet, Statement of Operations and Statement of Cash Flows


	As of March 31, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Balance Sheet
Total assets	$	231,843,054	$	—	$	231,843,054
Liabilities and stockholders’ equity
Total current liabilities	$	390,929	$	—	$	390,929
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		11,624,170		11,624,170
Total liabilities		6,690,929		11,624,170		18,315,099
Class A common stock, $0.0001 par value; shares subject to possible redemption		220,152,120		(11,624,170)		208,527,950
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		98		117		215
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,046,721		731,633		5,778,354
Accumulated deficit		(47,389)		(731,750)		(779,139)
Total stockholders’ equity		5,000,005		—		5,000,005
Total liabilities and stockholders’ equity	$	231,843,054	$	—	$	231,843,054


	For the Three Months Ended March 31, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(87,774)	$	—	$	(87,774)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(416,670)		(416,670)
Financing cost - derivative warrant liabilities		—		(315,080)		(315,080)
Interest earned on marketable securities held in Trust Account		42,685		—		42,685
Total other (expense) income		42,685		(731,750)		(689,065)
Net loss	$	(45,089)	$	(731,750)	$	(776,839)

Basic and Diluted weighted-average Class A common stock		23,000,000				23,000,000
Basic and Diluted net loss per Class A common stock	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock		5,750,000		(593,407)		5,156,593
Basic and Diluted net loss per Class B common stock	$	(0.01)	$	(0.14)	$	(0.15)


	For the Three Months Ended March 31, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Unaudited Condensed Statement of Cash Flows
Net loss	$	(45,089)	$	(731,750)	$	(776,839)
Change in fair value of derivative warrant liabilities		—		416,670		416,670
Fiancing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(12,310)		(416,670)		(428,980)


	As of June 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Balance Sheet
Total assets	$	231,466,990	$	—	$	231,466,990
Liabilities and stockholders’ equity
Total current liabilities	$	130,600	$	—	$	130,600
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		14,127,170		14,127,170
Total liabilities		6,430,600		14,127,170		20,557,770
Class A common stock, $0.0001 par value; shares subject to possible redemption		220,036,380		(14,127,170)		205,909,210
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		100		141		241
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,162,459		3,234,609		8,397,068
Accumulated deficit		(163,124)		(3,234,750)		(3,397,874)
Total stockholders’ equity		5,000,010		—		5,000,010
Total liabilities and stockholders’ equity	$	231,466,990	$	—	$	231,466,990


	For the Three Months Ended June 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(194,558)	$	—	$	(194,558)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(2,503,000)		(2,503,000)
Interest earned on marketable securities held in Trust Account		78,823		—		78,823
Total other (expense) income		78,823		(2,503,000)		(2,424,177)
Net loss	$	(115,735)	$	(2,503,000)	$	(2,618,735)

Basic and Diluted weighted-average Class A common stock		23,000,000				23,000,000
Basic and Diluted net loss per Class A common stock	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock		5,750,000				5,750,000
Basic and Diluted net loss per Class B common stock	$	(0.03)	$	(0.43)	$	(0.46)


	For the Six Months Ended June 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(282,332)	$	—	$	(282,332)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(2,919,670)		(2,919,670)
Financing cost - derivative warrant liabilities		—		(315,080)		(315,080)
Interest earned on marketable securities held in Trust Account		121,508		—		121,508
Total other (expense) income		121,508		(3,234,750)		(3,113,242)
Net loss	$	(160,824)	$	(3,234,750)	$	(3,395,574)

Basic and Diluted weighted-average Class A common shares outstanding		23,000,000		—		23,000,000
Basic and Diluted net loss per Class A share	$	0.00		—	$	0.00
Basic and Diluted weighted-average Class B common shares outstanding		5,750,000		(296,703)		5,453,297
Basic and Diluted net loss per Class B share	$	(0.04)	$	(0.58)	$	(0.62)


	For the Six Months Ended June 30, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Unaudited Condensed Statement of Cash Flows
Net loss	$	(160,824)	$	(3,234,750)	$	(3,395,574)
Change in fair value of derivative warrant liabilities		—		2,919,670		2,919,670
Fiancing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(128,050)		(2,919,670)		(3,047,720)


	As of September 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Balance Sheet
Total assets	$	231,395,659	$	—	$	231,395,659
Liabilities and stockholders’ equity
Total current liabilities	$	196,929	$	—	$	196,929
Deferred underwriting commissions		6,300,000		—		6,300,000
Derivative warrant liabilities		—		16,406,170		16,406,170
Total liabilities		6,496,929		16,406,170		22,903,099
Class A common stock, $0.0001 par value; shares subject to possible redemption		219,898,720		(16,406,170)		203,492,550
Stockholders’ equity
Preferred stock- $0.0001 par value		—		—		—
Class A common stock - $0.0001 par value		101		164		265
Class B common stock - $0.0001 par value		575		—		575
Additional paid-in-capital		5,300,118		5,513,586		10,813,704
Accumulated deficit		(300,784)		(5,513,750)		(5,814,534)
Total stockholders’ equity		5,000,010		—		5,000,010
Total liabilities and stockholders’ equity	$	231,395,659	$	—	$	231,395,659


	Three Months Ended September 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(198,480)	$	—	$	(198,480)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(2,279,000)		(2,279,000)
Interest income from investments in Trust Account		73,393		—		73,393
Income tax expense		(12,573)		—		(12,573)
Total other (expense) income		60,820		(2,279,000)		(2,218,180)
Net loss	$	(137,660)	$	(2,279,000)	$	(2,416,660)

Basic and Diluted weighted-average Class A common stock		23,000,000				23,000,000
Basic and Diluted net loss per Class A common stock	$	0.00			$	0.00
Basic and Diluted weighted-average Class B common stock		5,750,000				5,750,000
Basic and Diluted net loss per Class B common stock	$	(0.02)	$	(0.40)	$	(0.42)


	For the Nine Months Ended September 30, 2020
	As Previously Reported		Restatement Adjustment		As Restated

Unaudited Condensed Statement of Operations
Loss from operations	$	(480,812)	$	—	$	(480,812)
Other (expense) income:
Change in fair value of derivative warrant liabilities		—		(5,198,670)		(5,198,670)
Financing cost - derivative warrant liabilities		—		(315,080)		(315,080)
Interest income from investments in Trust Account		194,901		—		194,901
Income tax expense		(12,573)		—		(12,573)
Total other (expense) income		182,328		(5,513,750)		(5,331,422)
Net loss	$	(298,484)	$	(5,513,750)	$	(5,812,234)

Basic and Diluted weighted-average Class A common shares outstanding		23,000,000		—		23,000,000
Basic and Diluted net loss per Class A share	$	0.00		—	$	0.00
Basic and Diluted weighted-average Class B common shares outstanding		5,750,000		(197,080)		5,552,920
Basic and Diluted net loss per Class B share	$	(0.05)	$	(1.00)	$	(1.05)


	For the Nine Months Ended September 30, 2020
	As Previously		Restatement
	Reported		Adjustment		As Restated
Unaudited Condensed Statement of Cash Flows
Net loss	$	(298,484)	$	(5,513,750)	$	(5,812,234)
Change in fair value of derivative warrant liabilities		—		5,198,670		5,198,670
Fiancing Cost- derivative warrant liabilities		—		315,080		315,080
Initial value of Class A common stock subject to possible redemption		220,164,430		(11,207,500)		208,956,930
Change in fair value of Class A common stock subject to possible redemption		(265,710)		(5,198,670)		(5,464,380)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Taxes

Schedule of components of income tax provision (benefit)


	December 31, 2020		December 31, 2019
Current
Federal	$	11,434	$	—
State		—		—
Deferred
Federal		(101,676)		(483)
State		—		—
Valuation allowance		101,676		483
Income tax provision		11,434		—

Schedule of Company's net deferred tax assets


	December 31, 2020		December 31, 2019
Deferred tax assets:
Start-up/Organization costs	$	101,676	$	315
Net operating loss carryforwards		—		168
Total deferred tax assets		101,676		483
Valuation allowance		(101,676)		(483)
Deferred tax asset, net of allowance	$	—	$	—

Schedule of reconciliation of the statutory federal income tax rate (benefit) to the Company's effective tax rate


	December 31, 2020		December 31, 2019
Statutory federal income tax	$	(1,748,979)	$	(483)
Change in fair value of derivative warrant liabilities		(1,450,150)		—
Financing costs - derivative warrant liabilities		(2,503.20)		—
Change in valuation allowance		3,213,065		483
Income tax expense	$	11,434	$	—

Organization, Business Operations and Basis of Presentation - Financing (Details) - USD ($)		2 Months Ended	12 Months Ended
	Mar. 13, 2020	Dec. 31, 2019	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Share price			$ 10.00
Offering costs		$ 0	$ 4,125,486
Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued	23,000,000
Share price	$ 10.00
Proceeds from issuance of shares	$ 230,000,000
Offering costs	10,400,000
Deferred underwriting commissions	$ 6,300,000
Number of warrants to purchase shares issued (in shares)			5,750,000
Private Placement
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued (in shares)			3,733,334
Price of warrants			$ 1.50
Proceeds from issuance of warrants			$ 5,600,000
Over-allotment
Subsidiary, Sale of Stock [Line Items]
Number of shares issued	3,000,000

Organization, Business Operations and Basis of Presentation - Trust Account (Details)	12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares
Organization, Business Operations and Basis of Presentation
Principal deposited in Trust Account	$ 230,000,000
Obligation to redeem Percentage of Common Stock With Respect To Any Other Material Provision Relating To Stockholders' Rights Or Pre-Initial Business Combination Activity	100.00%
Redemption of common stock included in the units sold in public offering (as a percent)	100.00%
Threshold period from closing of public offering the company is obligated to complete business combination	24 months
Cash equal to pro rata share calculated based on business days prior to consummation of business combination (in days)	2 days
Cash equal to pro rata share calculated based on business days prior to consummation of tender offer (in days)	2 days
Minimum net tangible assets upon consummation of the Company's initial Business Combination and after payment of underwriters fees and commissions	$ 5,000,001
Share price \| $ / shares	$ 10.00
Threshold business days for redemption of shares of trust account	10 days
Maximum net interest to pay dissolution expenses	$ 500,000
Minimum net interest to pay dissolution expenses	$ 100,000

Organization, Business Operations and Basis of Presentation - Liquidity (Details) - USD ($)	2 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Organization, Business Operations and Basis of Presentation
Operating bank account							$ 900,000
Working capital							800,000
Interest income							254,000
Investment Income, Interest	$ 0	$ 73,393	$ 78,823	$ 42,685	$ 121,508	$ 194,901	254,149
Maximum net interest to pay dissolution expenses							500,000
Contribution from sponsor							25,000
Note from sponsor							200,000
Amounts outstanding under any Working Capital Loan							$ 0

Restatement of previously issued financial statements - Effect of restatement on balance sheets (Details) - USD ($)

Dec. 31, 2020

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Oct. 31, 2019

Balance sheet

$ 231,323,610

$ 231,395,659

$ 231,466,990

$ 231,843,054

$ 50,000

267,550

196,929

130,600

390,929

27,300

6,300,000

18,791,170

16,406,170

14,127,170

11,624,170

Class A common stock, $0.0001 par value; 21,975,605 and -0- shares subject to possible redemption at $10.00 per share at December 31, 2020 and December 31, 2019, respectively

25,358,720

22,903,099

20,557,770

18,315,099

27,300

200,964,880

203,492,550

205,909,210

208,527,950

13,341,349

10,813,704

8,397,068

5,778,354

24,425

(8,342,204)

(5,814,534)

(3,397,874)

(779,139)

(2,300)

5,000,010

5,000,005

22,700

$ 0

231,323,610

231,395,659

231,466,990

231,843,054

50,000

Class A common stock

290

265

241

215

575

^[1]

575

$ 575

^[1]

As previously reported

Balance sheet

231,323,610

231,395,659

231,466,990

231,843,054

267,550

196,929

130,600

390,929

6,300,000

Class A common stock, $0.0001 par value; 21,975,605 and -0- shares subject to possible redemption at $10.00 per share at December 31, 2020 and December 31, 2019, respectively

6,567,550

6,496,929

6,430,600

6,690,929

219,756,050

219,898,720

220,036,380

220,152,120

5,442,787

5,300,118

5,162,459

5,046,721

(443,454)

(300,784)

(163,124)

(47,389)

5,000,010

5,000,005

As previously reported | Class A common stock

231,323,610

231,395,659

231,466,990

231,843,054

As previously reported | Class B common stock

102

101

100

575

Restatement Adjustment

18,791,170

16,406,170

14,127,170

11,624,170

Class A common stock, $0.0001 par value; 21,975,605 and -0- shares subject to possible redemption at $10.00 per share at December 31, 2020 and December 31, 2019, respectively

18,791,170

16,406,170

14,127,170

11,624,170

(18,791,170)

(16,406,170)

(14,127,170)

(11,624,170)

7,898,562

5,513,586

3,234,609

731,633

Restatement Adjustment | Class A common stock

(7,898,750)

(5,513,750)

(3,234,750)

(731,750)

$ 188

$ 164

$ 141

$ 117

[1]

Restatement of previously issued financial statements - Effect of restatement on statements of operations (Details) - USD ($)	2 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Statement of Operations
Loss from operations	$ (2,300)	$ (198,480)	$ (194,558)	$ (87,774)	$ (282,332)	$ (480,812)	$ (683,869)
Other (expense) income:
Change in fair value of derivative warrant liabilities	0	(2,279,000)	(2,503,000)	(416,670)	(2,919,670)	(5,198,670)	(7,583,670)
Financing costs - derivative warrant liabilities	0			(315,080)	(315,080)	(315,080)	(315,080)
Interest income from investments in Trust Account	0	73,393	78,823	42,685	121,508	194,901	254,149
Income tax expense	0	12,573				12,573	(11,434)
Total other (expense) income		(2,218,180)	(2,424,177)	(689,065)	(3,113,242)	(5,331,422)	(7,656,035)
Net loss	$ (2,300)	$ (2,416,660)	$ (2,618,735)	$ (776,839)	$ (3,395,574)	$ (5,812,234)	(8,339,904)
Class A common stock
Other (expense) income:
Interest income from investments in Trust Account							$ 254,000
Weighted average shares outstanding	0	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000
Basic and diluted net loss per share	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Class B common stock
Other (expense) income:
Net loss	$ (2,300)						$ (8,300,000)
Weighted average shares outstanding	5,000,000	5,750,000	5,750,000	5,156,593	5,453,297	5,552,920	5,602,459
Basic and diluted net loss per share	$ 0.00	$ (0.42)	$ (0.46)	$ (0.15)	$ (0.62)	$ (1.05)	$ (1.49)
As previously reported
Statement of Operations
Loss from operations		$ (198,480)	$ (194,558)	$ (87,774)	$ (282,332)	$ (480,812)	$ (683,869)
Other (expense) income:
Interest income from investments in Trust Account		73,393	78,823	42,685	121,508	194,901	254,149
Income tax expense		12,573				12,573	(11,434)
Total other (expense) income		60,820	78,823	42,685	121,508	182,328	242,715
Net loss		$ (137,660)	$ (115,735)	$ (45,089)	$ (160,824)	$ (298,484)	$ (441,154)
As previously reported \| Class A common stock
Other (expense) income:
Weighted average shares outstanding		23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000
Basic and diluted net loss per share		$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
As previously reported \| Class B common stock
Other (expense) income:
Weighted average shares outstanding		5,750,000	5,750,000	5,750,000	5,750,000	5,750,000	5,602,459
Basic and diluted net loss per share		$ (0.02)	$ (0.03)	$ (0.01)	$ (0.04)	$ (0.05)	$ (0.08)
Restatement Adjustment
Other (expense) income:
Change in fair value of derivative warrant liabilities		$ (2,279,000)	$ (2,503,000)	$ (416,670)	$ (2,919,670)	$ (5,198,670)	$ (7,583,670)
Financing costs - derivative warrant liabilities				(315,080)	(315,080)	(315,080)	(315,080)
Total other (expense) income		(2,279,000)	(2,503,000)	(731,750)	(3,234,750)	(5,513,750)	(7,898,750)
Net loss		$ (2,279,000)	$ (2,503,000)	$ (731,750)	$ (3,234,750)	$ (5,513,750)	$ (7,898,750)
Restatement Adjustment \| Class B common stock
Other (expense) income:
Weighted average shares outstanding				(593,407)	(296,703)	(197,080)
Basic and diluted net loss per share		$ (0.40)	$ (0.43)	$ (0.14)	$ (0.58)	$ (1.00)	$ (1.41)

Restatement of previously issued financial statements - Effect of restatement on statements of cash flows (Details) - USD ($)		2 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 13, 2020	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Statement of Cash Flows
Net loss		$ (2,300)			$ (776,839)	$ (3,395,574)	$ (5,812,234)	$ (8,339,904)
Change in fair value of derivative warrant liabilities		0	$ 2,279,000	$ 2,503,000	416,670	2,919,670	5,198,670	7,583,670
Financing Cost- derivative warrant liabilities		0			315,080	315,080	315,080	315,080
Initial value of Class A common stock subject to possible redemption		0			208,956,930	208,956,930	208,956,930	208,956,930
Change in fair value of Class A common stock subject to possible redemption		$ 0			(428,980)	(3,047,720)	(5,464,380)	(7,992,050)
Increase to the derivative liabilities	$ 11,200,000
Increase to additional paid-in-capital	$ 300,000							1,120,000
As previously reported
Statement of Cash Flows
Net loss					(45,089)	(160,824)	(298,484)	(441,154)
Initial value of Class A common stock subject to possible redemption					220,164,430	220,164,430	220,164,430	220,164,430
Change in fair value of Class A common stock subject to possible redemption					(12,310)	(128,050)	(265,710)	(408,380)
Restatement Adjustment
Statement of Cash Flows
Net loss					(731,750)	(3,234,750)	(5,513,750)	(7,898,750)
Change in fair value of derivative warrant liabilities			$ 2,279,000	$ 2,503,000	416,670	2,919,670	5,198,670	7,583,670
Financing Cost- derivative warrant liabilities					315,080	315,080	315,080	315,080
Initial value of Class A common stock subject to possible redemption					(11,207,500)	(11,207,500)	(11,207,500)	(11,207,500)
Change in fair value of Class A common stock subject to possible redemption					$ (416,670)	$ (2,919,670)	$ (5,198,670)	$ (7,583,670)

Summary of Significant Accounting Policies - Concentration of Credit Risk, Cash and Cash Equivalents and Class A common stock subject to possible redemption (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies
Cash equivalents	$ 0	$ 0
Shares subject to possible redemption	20,096,488

Summary of Significant Accounting Policies - Derivative Warrant Liabilities (Details)	Dec. 31, 2020 shares
Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued (in shares)	3,733,334
Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued (in shares)	5,750,000
Private Placement
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued (in shares)	3,733,334

Summary of Significant Accounting Policies - Net Loss Per Share of Common Stock (Details) - USD ($)		2 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Feb. 19, 2020	Dec. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest income available in the Trust Account for tax obligations		$ 0	$ 73,393	$ 78,823	$ 42,685	$ 121,508	$ 194,901	$ 254,149
Working capital								800,000
Net loss		2,300	$ 2,416,660	$ 2,618,735	$ 776,839	$ 3,395,574	$ 5,812,234	8,339,904
Class A common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest income available in the Trust Account for tax obligations								254,000
Maximum allowance for tax obligations								211,000
Working capital								43,000
Class B common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss		$ 2,300						8,300,000
Income attributable to Class A common stock								0
Net loss after distributed earnings								$ 8,300,000
Number of shares subject to forfeiture (in shares)	750,000	750,000
Private placement warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded since their inclusion would be anti-dilutive								9,483,334

Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)	2 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Summary of Significant Accounting Policies
Unrecognized tax benefits	$ 0			$ 0
Amounts accrued for the payment of interest and penalties	0			0
Income tax expense	$ 0	$ (12,573)	$ (12,573)	$ 11,434

Initial Public Offering (Details) - USD ($)		2 Months Ended	12 Months Ended
Initial Public Offering (Details) - USD ($)	Mar. 13, 2020	Dec. 31, 2019	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Price per unit			$ 10.00
Offering costs		$ 0	$ 4,125,486
Deferred underwriting commissions in connection with the initial public offering		$ 0	$ 6,300,000
Deerfield Funds
Subsidiary, Sale of Stock [Line Items]
Additional units issued	5,000,000
Class A common stock
Subsidiary, Sale of Stock [Line Items]
Number of shares in a unit	1
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Number of warrants in a unit	0.25
Number of shares issuable per warrant	1
Exercise price of warrants (in dollars per share)	$ 11.50
Public Offering
Subsidiary, Sale of Stock [Line Items]
Additional units issued	23,000,000
Price per unit	$ 10.00
Proceeds from issuance of shares	$ 230,000,000
Offering costs	10,400,000
Deferred underwriting commissions in connection with the initial public offering	$ 6,300,000
Over-allotment
Subsidiary, Sale of Stock [Line Items]
Additional units issued	3,000,000

Related Party Transactions - Founder Shares (Details) - USD ($)

1 Months Ended

2 Months Ended

12 Months Ended

Feb. 19, 2020

Dec. 30, 2019

Jan. 31, 2020

Dec. 31, 2019

Dec. 31, 2020

Capital contribution

$ 223,272,500

Total number of shares after stock split (in shares)

Capital contribution

^[1],[2]

$ 25,000

5,750,000

Number of shares subject to forfeiture (in shares)

750,000

Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination

1 year

Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)

$ 12.00

Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination

20 days

Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination

30 days

Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences

150 days

Class B common stock | Sponsor

Number of shares issued (in shares)

4,312,500

Capital contribution

$ 25,000

Capital contribution (in dollars per share)

$ 0.004

Number of shares held (in shares)

3,922,500

Number of shares held after stock split (in shares)

5,360,000

Class B common stock | Sponsor | Steven Hochberg

Class B common stock | Sponsor | Christopher Wolfe

100,000

Class B common stock | Sponsor | Richard Barasch

100,000

Class B common stock | Sponsor | Dr. Jennifer Carter

100,000

Class B common stock | Sponsor | Dr. Mohit Kaushal

30,000

Class B common stock | Sponsor | Dr. Gregory Sorensen

30,000

30,000

[1]	The share amounts have been retroactively restated to reflect the split of Class B common stock on February 19, 2020 resulting in 5,750,000 shares outstanding (see Note 4).
[2]	This number excludes an aggregate of up to 750,000 Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Related Party Transactions - Private Placement Warrants (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020	Mar. 13, 2020
Class A common stock
Related Party Transaction [Line Items]
Number of shares issuable per warrant (in shares)		1
Exercise price of warrants (in dollars per share)		$ 11.50
Private Placement
Related Party Transaction [Line Items]
Number of warrants to purchase shares issued (in shares)	3,733,334
Price of warrants (in dollars per share)	$ 1.50
Proceeds from issuance of warrants	$ 5.6
Private Placement \| Class A common stock
Related Party Transaction [Line Items]
Number of shares issuable per warrant (in shares)	1
Exercise price of warrants (in dollars per share)	$ 11.50

Related Party Transaction - Other Transactions (Details) - USD ($)		2 Months Ended	3 Months Ended	12 Months Ended
	Mar. 13, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Proceeds received from note payable to related party		$ 0		$ 200,000
Accrued expenses - related parties			$ 17,500	17,500
Sponsor Loan
Related Party Transaction [Line Items]
Proceeds received from note payable to related party	$ 200,000
Sponsor Loan \| Maximum
Related Party Transaction [Line Items]
Amounts of transaction				200,000
Administrative Services Agreement
Related Party Transaction [Line Items]
Expenses per month				10,000
Total expenses incurred		0	100,000
Accrued expenses - related parties		0	10,000	10,000
Wolfe Strategic Services Agreement
Related Party Transaction [Line Items]
Expenses per month				7,500
Total expenses incurred		0		75,000
Accrued expenses - related parties		$ 0	$ 7,500	7,500
Working Capital Loans
Related Party Transaction [Line Items]
Proceeds received from note payable to related party				$ 0
Price of warrants (in dollars per share)			$ 1.50	$ 1.50
Working Capital Loans \| Maximum
Related Party Transaction [Line Items]
Loans convertible into warrants			$ 1,100,000	$ 1,100,000

Commitments and Contingencies (Details) - USD ($)		12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Mar. 13, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Underwriting discount (as a percent)		2.00%
Underwriting discount paid		$ 3,600,000
Deferred Underwriting Fees, Percentage		3.50%
Deferred underwriting fees		$ 6,300,000	$ 6,300,000	$ 6,300,000	$ 6,300,000
Over-allotment
Subsidiary, Sale of Stock [Line Items]
Overallotment option period		45 days
Additional units issued	3,000,000

Derivative Warrant Liabilities - Warrants (Details)	12 Months Ended
Derivative Warrant Liabilities - Warrants (Details)	Dec. 31, 2020 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Public Warrants exercisable term after the completion of a business combination	30 days
Public Warrants exercisable term from the closing of the public offering	12 months
Threshold maximum period for filing registration statement after business combination	15 days
Public Warrants expiration term	5 years
Redemption price per public warrant (in dollars per share)	$ 0.01
Minimum threshold written notice period for redemption of public warrants	30 days
Redemption of warrants commencing ninety days after the warrants become exercisable
Class of Warrant or Right [Line Items]
Redemption price per public warrant (in dollars per share)	$ 0.10
Minimum threshold written notice period for redemption of public warrants	30 days
Redemption period after the public warrants become exercisable	90 days
Private Placement Warrants
Class of Warrant or Right [Line Items]
Number of warrant outstanding \| shares	3,733,334
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination	30 days
Public warrants
Class of Warrant or Right [Line Items]
Number of warrant outstanding \| shares	5,750,000
Class A common stock
Class of Warrant or Right [Line Items]
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination	30 days
Stock price trigger for redemption of public warrants (in dollars per share)	$ 18.00
Threshold trading days for redemption of public warrants	20 days
Threshold consecutive trading days for redemption of public warrants	30 days
Number of trading days on which fair market value of shares is reported \| $	10
Class A common stock \| Redemption of warrants commencing ninety days after the warrants become exercisable
Class of Warrant or Right [Line Items]
Stock price trigger for redemption of public warrants (in dollars per share)	$ 10.00

Stockholders' Equity - Common Stock (Details) - $ / shares			2 Months Ended	12 Months Ended
	Feb. 19, 2020	Dec. 30, 2019	Dec. 31, 2019	Dec. 31, 2020	Mar. 13, 2020
Class of Stock [Line Items]
Common shares, outstanding including shares subject to possible redemption			0
Common shares, shares outstanding (in shares)			5,750,000	5,750,000
Class A common stock
Class of Stock [Line Items]
Common shares, shares authorized (in shares)			100,000,000	100,000,000
Common shares, par value (in dollars per share)			$ 0.0001	$ 0.0001	$ 0.0001
Common shares, issued including shares subject to possible redemption				23,000,000
Common shares, shares issued (in shares)			0	2,903,512
Common shares, outstanding including shares subject to possible redemption				23,000,000
Common shares, shares outstanding (in shares)			0	1,024,395
Common stock, shares subject to possible redemption				21,975,605
Number of common stock issuable pursuant to Initial Business Combination, as a percent of outstanding shares				20.00%
Class B common stock
Class of Stock [Line Items]
Common shares, shares authorized (in shares)			10,000,000	10,000,000
Common shares, par value (in dollars per share)			$ 0.0001	$ 0.0001
Common shares, shares issued (in shares)			5,750,000	5,750,000
Common shares, shares outstanding (in shares)			5,750,000	5,750,000
Common shares, votes per share				$ 1
Total number of shares after stock split (in shares)	5,750,000
Number of shares subject to forfeiture (in shares)	750,000		750,000
Beneficial ownership (as a percent)				20.00%
Number of Class A common stock issued upon conversion of each share (in shares)				1
Class B common stock \| Sponsor
Class of Stock [Line Items]
Number of shares issued (in shares)	4,312,500	4,312,500
Number of shares held after stock split (in shares)	5,360,000

Stockholders' Equity - Preferred Stock (Details) - $ / shares	Dec. 31, 2020	Dec. 31, 2019	Nov. 30, 2019
Stockholders' Equity
Preferred shares, shares authorized	1,000,000	1,000,000
Preferred shares, par value	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0	0
Preferred shares, shares outstanding	0	0	0

Fair Value Measurements (Details) - USD ($)	12 Months Ended
Fair Value Measurements (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liabilities	$ 18,791,170	$ 16,406,170	$ 14,127,170	$ 11,624,170
Assets or liabilities measured at fair value					$ 0
Measured on a recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value assets level 1 to level 2 transfers	0
Fair value assets level 2 to level 1 transfers	0
Fair value assets transferred into (out of) level 3	0
Measured on a recurring basis \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	230,254,149
Measured on a recurring basis \| Level 1 \| U.S. Treasury Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	230,253,395
Measured on a recurring basis \| Level 1 \| Cash and Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	754
Measured on a recurring basis \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	0
Measured on a recurring basis \| Level 2 \| U.S. Treasury Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	0
Measured on a recurring basis \| Level 2 \| Cash and Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	0
Measured on a recurring basis \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	0
Measured on a recurring basis \| Level 3 \| U.S. Treasury Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	0
Measured on a recurring basis \| Level 3 \| Cash and Cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets held in Trust Account	0
Private Placement Warrants \| Measured on a recurring basis \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liabilities	0
Private Placement Warrants \| Measured on a recurring basis \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liabilities	0
Private Placement Warrants \| Measured on a recurring basis \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liabilities	7,578,670
Public warrants \| Measured on a recurring basis \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liabilities	11,212,500
Public warrants \| Measured on a recurring basis \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liabilities	0
Public warrants \| Measured on a recurring basis \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liabilities	$ 0

Fair Value Measurements - Quantitative information regarding Level 3 fair value measurements (Details) - Level 3	Dec. 31, 2020	Mar. 13, 2020
Stock price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	10.80	9.71
Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	24.0	18.2
Expected life of the options to convert
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	5.75	6.55
Risk-free rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.47	0.85
Dividend yield
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.0	0.0

Fair Value Measurements - Change in the fair value of the derivative warrant liabilities measured with Level 3 inputs (Details) - Level 3	12 Months Ended
	Dec. 31, 2020 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Level 3 derivative warrant liabilities at January 1, 2020	$ 0
Issuance of Public and Private Warrants	11,207,500
Transfer of Public warrant to Level 1	(6,957,500)
Change in fair value of derivative warrant liabilities	3,328,670
Level 3 derivative warrant liabilities at December 31, 2020	$ 7,578,670

Quarterly financial information (unaudited) - Condensed Balance Sheet (Details) - USD ($)

Dec. 31, 2020

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Oct. 31, 2019

Unaudited Condensed Balance Sheet

$ 231,323,610

$ 231,395,659

$ 231,466,990

$ 231,843,054

$ 50,000

267,550

196,929

130,600

390,929

27,300

6,300,000

18,791,170

16,406,170

14,127,170

11,624,170

Class A common stock, $0.0001 par value; shares subject to possible redemption

25,358,720

22,903,099

20,557,770

18,315,099

27,300

200,964,880

203,492,550

205,909,210

208,527,950

13,341,349

10,813,704

8,397,068

5,778,354

24,425

(8,342,204)

(5,814,534)

(3,397,874)

(779,139)

(2,300)

5,000,010

5,000,005

22,700

$ 0

231,323,610

231,395,659

231,466,990

231,843,054

50,000

Class A common stock

290

265

241

215

575

^[1]

575

$ 575

^[1]

As previously reported

Unaudited Condensed Balance Sheet

231,323,610

231,395,659

231,466,990

231,843,054

267,550

196,929

130,600

390,929

6,300,000

Class A common stock, $0.0001 par value; shares subject to possible redemption

6,567,550

6,496,929

6,430,600

6,690,929

219,756,050

219,898,720

220,036,380

220,152,120

5,442,787

5,300,118

5,162,459

5,046,721

(443,454)

(300,784)

(163,124)

(47,389)

5,000,010

5,000,005

As previously reported | Class A common stock

231,323,610

231,395,659

231,466,990

231,843,054

As previously reported | Class B common stock

102

101

100

575

Restatement Adjustment

18,791,170

16,406,170

14,127,170

11,624,170

Class A common stock, $0.0001 par value; shares subject to possible redemption

18,791,170

16,406,170

14,127,170

11,624,170

(18,791,170)

(16,406,170)

(14,127,170)

(11,624,170)

7,898,562

5,513,586

3,234,609

731,633

Restatement Adjustment | Class A common stock

(7,898,750)

(5,513,750)

(3,234,750)

(731,750)